



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

☆ **Spotlight on Special Topics**

COVID-19 OUTCOMES AND CLINICAL CORRELATION WITH MYOCARDIAL INJURY ON ADMISSION TO HOSPITAL

Moderated Poster Contributions
Saturday, May 15, 2021, 10:30 a.m.-10:40 a.m.

Session Title: Markers to Measure Mortality: Biomarkers, Inflammatory Markers and Other Markers of Outcomes in Patients with COVID-19 Infection

Abstract Category: 61. Spotlight on Special Topics: Coronavirus Disease (COVID-19)

Presentation Number: 1088-07

Authors: *Gavin Manmathan, Debbie Falconer, Samuel Conway, Athanasios Kosovitsas, Zakee Abdi, Alan Hunter, Callum Little, Colette Smith, Sabine Kinloch-de Loes, Margaret A. Johnson, Roby Rakhit, Royal Free Hospital, London, United Kingdom, University College London, London, United Kingdom*

Background: Risk stratification in COVID-19 is crucial to optimise treatment strategies. We evaluated the use of biomarkers on admission to hospital and the impact on mortality and morbidity.

Methods: Consecutive patients with COVID-19(PCR+) were included in this retrospective, observational study.1675 patients were PCR+ and 1036 had a high sensitivity troponin T(hsTropT) on admission. 371 patients were hsTropT-<15ng/L, 664 were in the myocardial injury group(MIG; hsTropT ≥15ng/L). Baseline data was compared, as were primary outcomes of death, ICU admission and COVID severity. Secondary outcomes included ARDS, myocardial infarction (MI); comparison with biomarkers: NT- proBNP, d-dimer, CRP,LDH and ferritin.

Results: MIG patients were older(75±14v55±14yrs;p<0.001), had more comorbidities eg. diabetes(37v13%), hypertension(34v29%), ischemic heart disease(16v2%)[p<0.01]. Mortality was higher in the MIG(46v8%;p<0.001), as was critical COVID (47v19%;p<0.001), ARDS(20v4%;p<0.001), and Type1 MI(1.6v0.01%;p<0.01). Analysis of biomarkers on admission (Fig 1.) demonstrated hsTropT and NT-proBNP (AUC 0.75 CI 0.69-0.81) sensitivity 83;85% and specificity 52;58%, respectively at predicting death.

Conclusion: Early detection of elevated hsTropT and NT-proBNP predicts mortality and morbidity in patients with COVID-19. Routine measurement of cardiac biomarkers should be considered in these patients at the time of admission in order to optimise risk stratification and monitoring .

Figure 1. ROC curve analysis of admission biomarkers against death.

